Juno Therapeutics Inc

Juno Therapeutics — Investor Presentation (September 2015)

25 slides from Juno Therapeutics's investor presentation, Sep 15, 2015

  1. Slide 1: Corporate Juno Therapeutics Presentation

    Exhibit 99.1 Corporate Juno Therapeutics Presentation Proprietary Materials September 2015

  2. Slide 2: Forward-Looking Statements

    Forward-Looking This the such trends and developments, industry; assumptions These performance. to, approval infrastructure; third-party manufacture candidates candidates; these Securities Commission. statements 2Juno any risks risks process presentation forward-looking Therapeutics forward-looking

  3. Slide 3: Juno Therapeutics overview and key points

    Re-engaging Founded Investing Enrolling Ten Celgene Deep 3Junotherapeutic Therapeutics experience collaboration on in first pipeline the the pivotal candidates premise immune and Proprietary and atrial drives significant that platform system with against engineered global Materials potential toinves

  4. Slide 4: Compelling evidence of CD19 CAR T cells in ALL and NHL

    Compelling ALL Our NHL Day nced)Lymphoma)with)CD19) 4(1) Junoearly 28 Patient Patient After ORR experience evidence Before Before CD19 of 62% Therapeutics CD19 CD19 in of forlymphoma leukemia rapid patients Day ProprietaryCARtumor CAR 37 Ttrials treated After cells demonstrates Tshrinkage Materials

  5. Slide 5: Engineer, expand and industrialize T cell manufacturing platform

    Engineer Clinical Expansion Automation Turnaround 5Juno Therapeutics Proprietary Activity TPotency cells time Closed to Reagents Cost Cryopreservation Proprietary recognize Persistence platform Structure Scalable and Materials Patient kill Industrialization cancer process Convenience cells

  6. Slide 6: Exploit Juno's value creation goals

    Exploit Juno’s value Translational Beyond Auto-immune Celgene to Target ROR-1 MUC-16 L1CAM Transform WT-1 JCAR017 JCAR014 PDL-1 Execute First Best CD19- Human Building class 6Juno Solid in Therapeutics capabilities creation Selection goals Combination Disease: Class: Armored CD19: the B-Cell Tumors

  7. Slide 7: Juno's value creation goals

    Juno’s value Translational Beyond Auto-immune Celgene to Target ROR-1 MUC-16 L1CAM Transform WT-1 JCAR017 JCAR014 PDL-1 Execute First Best CD19- Human Building class 7Juno Solid in Therapeutics capabilities creation Selection goals Combination Disease: Class: Armored CD19: B-Cell Tumors Leukemia Oth

  8. Slide 8: Juno CD19 product candidates results

    Juno to Goal Product r/r Trial Evaluable Complete Severe (1) (5)rapid (2) (4) Adult 8Juno CD19 N First-in-class Cytokine Neurotoxicity confusion=& Candidate ALL significant other (3) With 39 Response Molecular =significant central One experience 38 N respect or r/r =Evaluable Release Pediatric 24 pa

  9. Slide 9: JCAR015 overall survival in adult ALL

    JCAR015 Survival Overall All MRD+ MRD+CR Post MRD-CR Historical Source: MRD 9Juno Patients CAR Therapeutics =includes Survival: MSK minimal Compares SOC Patients: adult Median Patients: Post 2015 median ALL MRD+CR CAR residual Overall Proprietary Survival: Post ASCO Favorably Post trial Tsurvival CA

  10. Slide 10: Fludarabine and persistence data in adult ALL

    Fludarabine persistence Data CR MRD Median Cy±VP16 Flu/Cy, DFS Flu/Cy Juno 10 == Therapeutics for 17/17 negative disease-free =not DFS JCAR014 fludarabine =and reached dramatically 150 forCR increases patients days Proprietary in =survival; 16/17 & Adult cyclophosphamide; in improves DFSCR: R/R DL2

  11. Slide 11: Competitive multiple Adult ALL strategy

    Competitive multiple Adult 50 FIRST-IN- Breakthrough Two (one Enrollment Leverage Next Phase CLASS BEST-IN- Fully Human Juno re-treatment 11 evaluable infusions manufacturing Therapeutics generation Human ALL 2 CD19 1 pivotal ongoing morphologic Human go-to Learnings Fast began Advantage: patients S

  12. Slide 12: Juno's value creation goals

    Juno’s value Translational Beyond Auto-immune Celgene to Target ROR-1 MUC-16 L1CAM Transform WT-1 JCAR017 JCAR014 PDL-1 Execute First Best CD19- Human Building class Juno 12 Solid in Therapeutics capabilities creation Selection goals Combination Disease: Class: Armored CD19: B-Cell Tumors Leukemia O

  13. Slide 13: Non-Hodgkin Lymphoma: significant unmet need

    Non-Hodgkin Despite NHL Keys JCAR014 Multi-pronged Biology Juno 13 Therapeutics is to asignificant durable, and CD19 with progress Lymphoma strategy improved positive long-term Proprietary progress, suggest todisease. conditioning create –remissions The NHL NHL Materials Next aWe, best-in-class rema

  14. Slide 14: JCAR014: Improved NHL results with Flu/Cy conditioning

    JCAR014: Improved NHL Conditioning Dose CR Efficacy CR/PR (n=12) Toxicity Syndrome Severe *Neurotoxicity* 14 1 Therapeutics Flu/Cy Juno Results: Level 12 Cytokine (n=3) 36Neurotoxicity = 11fludarabine Cell (n=12) 1favorable 4All 43(n=6) Regimen regimens Expansion (n=12) Doses Release (n=3) (n=4) imp

  15. Slide 15: JCAR017 rationale in NHL

    Rationale NHL: 1Determine JCAR017 2Develop JCAR014 3Test CR multiple Enroll effects (e.g., =checkpoint Juno 15 readouts multi-center translational and expression Combination 4Documentedphase Test on CR inhibitor immune human trial Therapeutics complete 1 with will rate, lymphodepletion) persistence

  16. Slide 16: Juno's value creation goals

    Juno’s value Translational Beyond Auto-immune Celgene to Target ROR-1 MUC-16 L1CAM Transform WT-1 JCAR017 JCAR014 PDL-1 Execute First Best CD19- Human Building class Juno 16 Solid in Therapeutics capabilities creation Selection goals Combination Disease: Class: Armored CD19: B-Cell Tumors Leukemia O

  17. Slide 17: Systematic approach to solid tumors

    Systematic can Status inhibitor Demonstrate Understand may understand Identify Juno 17 translate be Therapeutics limiting the andhow approach and right into that tumor overcome the totargets solid TProprietary induce cells infiltrating activity intumors leukemia kill home epitope how of cancer Mater

  18. Slide 18: Apply insights to overcome tumor microenvironment

    ApplyTherapeutics tumor “Armored” Combination PD-L1 Leverage solid Juno 18 tumors microenvironment translational antibody insights CARs trial to with Checkpoint Proprietary insights Small GeneMolecule toEditing Materials Inhibitors overcome Modulation Modulating the T Cell Function

  19. Slide 19: Approach to identifying the right target

    Approach Proprietary CAR index naked Substantial Exploring targets Rigorous identification pre-clinical Pre-clinical programs Juno 19 Therapeutics Tdifferent antibodies novel cell target advancing to different in-house Bispecific testing therapeutic and identifying TCRs and than clinical Proprietary

  20. Slide 20: First set of solid tumor programs

    The first Active WT-1 AML L1CAM Neuroblastoma ROR-1 MUC-16 Tumors “Armored Ovarian Multiple Juno 20 Therapeutics /(TCR) and NSCLC (CAR) Expressed MUC-16 (CAR) set in-house / CAR” IL-12 Planned of15solid Overexpressed Preliminary Generally Overexpressed patients First is and Preliminary Proprietary P

  21. Slide 21: Juno's value creation goals

    Juno’s value Translational Beyond Auto-immune Celgene to Target ROR-1 MUC-16 L1CAM Transform WT-1 JCAR017 JCAR014 PDL-1 Execute First Best CD19- Human Building class Juno 21 Solid in Therapeutics capabilities creation Selection goals Combination Disease: Class: Armored CD19: B-Cell Tumors Leukemia O

  22. Slide 22: Competitive advantage through consolidation of technologies

    Our consolidation competitive FOUNDING INSTITUTIONS Opus PARTNERS Juno 22 Therapeutics Bio advantage ACADEMIC INSTITUTIONS of Proprietary multiple in this STRATEGIC evolving technologies Materials PARTNER field TECHNOLOGY is a DEVELOPMENT & ACQUISITIONS

  23. Slide 23: Celgene collaboration and expanded cooperation

    Solidifying transformative EXPANDED Cell Immuno-oncology BUSINESS A COOPERATION Enhanced immuno-oncology Juno 23 partner therapies, Therapeutics of capabilities leadership DEVELOPMENT choice CAPABILITIES small immunotherapies Proprietary assets combinations for molecules, to in cellular identify the

  24. Slide 24: A systematic approach to developing cellular therapies

    A systematic IDENTIFY CARs RIGHT Pre-clinical IMPROVE Multiple PERSISTENCE DEFINE Access CELL MODULATE Conditioning MICROENVIRONMENT CLINICIAN-CONTROLLED Ablation MANUFACTURING PROCESS Juno 24 Therapeutics POPULATION to TARGET co-stimulatory technologies OPTIMAL key DEVELOPMENT Human THE models appr

  25. Slide 25: Robust pipeline of programs

    Robust Active Program (Pediatric Adult (Adult Modulation, CD19: CD22: (B WT-1: (AML, L1CAM: MUC16 ROR-1: Juno 25 Cell Therapeutics ALL BALL JTCR016 B and JCAR015 JCAR017 JCAR014 JCAR021 “Armored” JCAR018 NSCLC) and Malignancies) CAR Cell &Description Cell JCAR023 ALL IL-12: Planned Phase diverse and

Juno Therapeutics — Investor Presentation (September 2015) on 6ix